TREATMENT
CENTER DIRECTORY
Grace
Person with PH1*

*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.

Find a treatment center

Use the Treatment Center Directory for OXLUMO® (lumasiran) below to find a healthcare center where you can receive your OXLUMO treatment.

Treatment Centers for OXLUMO are added on an ongoing basis and may not be in this locator tool yet. For additional treatment centers, please contact Alnylam Assist®.

eyelight

Visit: AlnylamAssist.com

Call: 1-833-256-2748 Monday-Friday, 8 AM-6 PM

The Treatment Center Directory for OXLUMO is an informational resource for locating a site of care administering OXLUMO. No fees or other remuneration have been or will be exchanged for a treatment center’s inclusion in this database. Inclusion of centers in this database is based on opt-in approval by authorized personnel for those sites listed. Alnylam Pharmaceuticals is not affiliated with, and inclusion in this database does not represent an endorsement of, recommendation for, or referral to, the treatment centers listed in this database. Likewise, participating centers do not endorse any Alnylam products and may not be currently administering any Alnylam products.

IMPORTANT SAFETY INFORMATION

The most common side effect of OXLUMO® (lumasiran) is injection site reaction (redness, swelling, pain, bruising, itching, and discoloration at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

WHAT IS OXLUMO?

OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine and blood in children and adults.  

For additional information about OXLUMO, please see the full Prescribing Information.